Editorial commentary: extended-spectrum β-lactamase-producing escherichia coli in the united states: time to rethink empirical treatment for suspected E. coli infections?

In this issue of Clinical Infectious Diseases, Doi et al report the results of a prospective observational study conducted among 5 hospitals and their affiliated clinics throughout the United States aimed at estimating the occurrence of community-acquired infections due to extended-spectrum β-lactamase (ESBL)– producing Escherichia coli [1]. Similar to… CONTINUE READING